Shares of NeoGenomics NEO decreased 0.1% in pre-market trading after the company reported Q1 results.
Quarterly Results
Earnings per share decreased 100.00% year over year to ($0.04), which missed the estimate of $0.01.
Revenue of $115,533,000 rose by 8.96% from the same period last year, which beat the estimate of $112,410,000.
Outlook
The upcoming fiscal year's EPS expected to be between ($0.27) and ($0.23).
The upcoming fiscal year's revenue expected to be between $490,000,000 and $510,000,000.
How To Listen To The Conference Call
Date: May 05, 2021
Time: 08:30 AM
ET Webcast URL: https://ir.neogenomics.com/ir-calendar
Recent Stock Performance
Company's 52-week high was at $61.57
52-week low: $25.19
Price action over last quarter: down 2.50%
Company Overview
NeoGenomics Inc operates a network of cancer-focused genetic testing laboratories in the United States as well as a laboratory in Switzerland. The company operates into two segments namely Clinical Services and Pharma Services. It offers types of genetic and molecular testing services namely Cytogenetics, Fluorescence In-Situ Hybridization, Flow cytometry, Immunohistochemistry, Molecular testing, Pathology consultation. The company generates revenue from Clinical Services.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.